Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 13/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486280 | 0.86 | HTR2C (0.43) | HTR2CSLC6A4HTR2BCYP11B1CYP11B2 | |
| SCHEMBL17485959 | 0.83 | DGAT1 (0.45) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17486255 | 0.81 | GRM2 (0.35) | CYP11B1CYP11B2 | |
| SCHEMBL17486288 | 0.81 | DYRK1B (0.34) | SMN1; SMN2 | |
| SCHEMBL17486252 | 0.76 | CYP11B1 (0.33) | CYP11B1CYP11B2CYP19A1SMN1; SMN2 | |
| SCHEMBL20805575 | 0.73 | ALDH1A1 (0.34) | SMN1; SMN2 | |
| SCHEMBL20805427 | 0.71 | HTR2C (0.48) | HTR2CSLC6A4HTR2BCYP11B1CYP11B2 | |
| SCHEMBL17485976 | 0.71 | DGAT1 (0.45) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17486254 | 0.69 | CYP11B1 (0.36) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17486282 | 0.69 | HTR2C (0.47) | HTR2CSLC6A4HTR2BCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | HTR2C 4357/4885SLC6A4 2877/4885HTR2B 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.